Aim: To test the effect of standardised coffee intake on postoperative bowel movement after elective colon resection. Method: Between 9/2014 and 12/2016 patients scheduled for elective colon surgery were randomized to receive either coffee (intervention group) or tea (control group). 150 ml of the respective beverage was consumed 3x/d every postoperative day until discharge. The primary endpoint was time to first bowel movement. Secondary endpoints included second bowel movement, use of laxative, insertion of nasogastric tube, length of hospital stay and postoperative complications. Results: A total of 115 patients were randomized: 56 were allocated to the coffee and 59 to the tea group. After coffee intake, the first bowel movement occurred after a median of 65.2 h (95% CI: 50.5-79.8) as compared to 74.1 h (95% CI: 60.7-87.5) in the control group (intention-to-treat analysis; P = 0.008). The hazard for earlier first bowel movement after coffee intake was 1.67 (95% CI: 1.14-2.44; P = 0.009). Furthermore, 7.1% of the patients in the coffee group experienced the first bowel movement within 24 h after surgery as compared to 1.7% in tea group. Conclusion: Coffee intake after elective colon resection leads to a faster recovery of bowel function. Therefore, coffee intake represents a simple and effective strategy to prevent postoperative ileus. Aim: Overall cancer risk following ileal pouch-anal anastomosis (IPAA) is unknown, and pouch cancer surveillance is controversial. This study aimed at determining the long-term risk of cancer in a national cohort of patients with ulcerative colitis and IPAA. Method: Data on cancers diagnosed after IPAA were extracted from the Danish Cancer Registry. Cancer incidence rates were compared between patients with IPAA and a comparable cohort. Results: Of 1723 patients with IPAA and ulcerative colitis operated between 1980-2010 were matched to 8,615 individuals from the background population. During 12.9 years of follow-up, two pouch cancers (0.12%) were found after 16 and 27 years, respectively. In the comparable cohort, 38 intestinal cancers (0.45%) were found, of which 35 were colorectal. Patients with IPAA had a higher risk of hepatobiliary cancer [incidence rate ratio (IRR) = 13.0 (95% CI: 3.1-76.1)]. The overall risk of cancer following IPAA was similar to that of the comparable cohort [IRR = 1.05 (0.84-1.31)]. Conclusion: Overall cancer risk following IPAA for UC is similar to the background population risk. Pouch cancer is very rare, and general surveillance seems unjustified. The increased risk of hepatobiliary cancer is similar to what is found in patients with ulcerative colitis and an intact colon and rectum.
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B3
The rectal cancer female sexuality score: development and validation of a scoring system for female sexual function after rectal cancer surgery A. Thyø Colorectal Surgical Unit, Aarhus University Hospital, Aarhus, Denmark, 2 Surgical Department, Randers, Denmark Aim: To develop and validate a simple scoring system intended to evaluate sexual function in women treated for rectal cancer.
Method: Using the Danish Colorectal Cancer Group's database, female patients diagnosed with rectal cancer between 2001-2014 were identified. Women who underwent abdomino-perineal resection, Hartmann's procedure or TME/PME were included. Participants filled in the validated Sexual Function Vaginal Changes questionnaire. Women declared to be sexually active were randomized into two groups; one for development and one for validation. Logistic regression analyses identified items for the score and multivariate analysis established a weighted score-value allocated to each item, adding up to the total score. The validity of the score was tested in the validation group. Results: Four hundred and sixty six sexually active women responded. The score includes seven items with a range of 0-29 points. Score ≥ 9 indicates sexual dysfunction. The score has a sensitivity/specificity of 76/75% detecting patients bothered by sexual dysfunction with negative impact on QOL. Conclusion: Living up to our demands for a short and easy-to-use validated tool, we have developed the Rectal Cancer Female Sexuality score. With high sensitivity it captures the essential problems of female sexuality seen from perspective of a surviving rectal cancer patient.
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FOxTROT: safety and feasibility of neoadjuvant chemotherapy in locally advanced, resectable colon cancer based on the phase III of a randomised controlled trial FOxTROT Collaborative Group University of Birmingham, Birmingham, UK Aim: Neoadjuvant chemotherapy is of proven benefit across several tumour types, but is under-investigated in resectable, locally advanced colon cancer. With completion of early follow up in 1053 patients with resectable colon cancer, this is the first large RCT to report on chemotherapy tolerance, down-staging and surgical morbidity following neoadjuvant therapy. Method: Of 1053 patients from 88 UK and 6 International centres (Sweden and Denmark) with radiological staging of T3 or T4 with extramural extension > 1 mm and no evidence of disseminated disease, completed recruitment in December 2016. Randomisation was (2:1) to receive 3 cycles of OxMdG prior to surgery or 12 cycles of OxMdG postoperatively. RAS wild-type patients were further randomised (1:1) to receive neoadjuvant panitumumab. Results: This Phase III will evaluate the impact of neoadjuvant chemotherapy on disease recurrence at 2 years, reporting in 2019. This presentation will be the first report of downstaging at the time of surgery, as well as safety and tolerability of neoadjuvant therapy. Conclusion: The FOxTROT trial is the largest RCT of neoadjuvant chemotherapy in the treatment of locally advanced, resectable colon cancer, and will inform the next generation of neoadjuvant trials internationally.
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Oncological outcomes after anastomotic leakage following surgery for rectal cancer in a randomized trial (COLOR II): increased risk of recurrence? T. Koedam, C. Deijen, B. Bootsma, E. de Lange-de Klerk, G. Kazemier, J. Tuynman, F. Daams & J. Bonjer VU University Medical Center, Amsterdam, The Netherlands Aim: Purpose of this study was to evaluate oncological outcome for patients with and without an anastomotic leakage after rectal cancer surgery in a randomized clinical trial (COLOR II). Method: Patients with a non-T4 rectal cancer included in the international, multicenter, non-inferior, open label, randomized trial COLOR II were analysed. Patients with abdominoperineal resection (APR) were excluded. Primary endpoint in COLOR II trial was local recurrence at 3-year follow-up, and secondary endpoints included anastomotic leakage. Results: The COLOR II trial included 1044 patients between January 2004 and May 2010. A total of 764 patients with a primary anastomosis or rectal stump after resection for rectal cancer were included. Eighty-four patients (11%) had an anastomotic leak after the primary surgery. Local recurrence was 4.6 and 13.3%, respectively (Log Rank, P = 0.003). Multivariate analysis showed that anastomotic leakage was an independent risk factor for local recurrence after resection for rectal cancer (OR 2.962; 95% CI 1.384-6.338, P = 0.005). Conclusion: The risk of local recurrence in patients with an anastomotic leakage after rectal cancer surgery is significantly increased when compared to patients without an anastomotic leakage. Clinical awareness throughout the follow-up is mandatory. 
